Virginie Gendreau-Sanguin

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion.

Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion.

Journal: JCI insight
Published: September 05, 2025

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

Journal: JCI insight
Published: August 20, 2025

EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.

EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.

Journal: EMBO reports
Published: July 15, 2025

HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.

HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.

Journal: Nature communications
Published: June 03, 2025

Osteopontin is a therapeutic target that drives breast cancer recurrence.

Osteopontin is a therapeutic target that drives breast cancer recurrence.

Journal: Nature communications
Published: April 05, 2024

Targeting fatty acid oxidation enhances response to HER2-targeted therapy.

Targeting fatty acid oxidation enhances response to HER2-targeted therapy.

Journal: Nature communications
Published: January 10, 2024

Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.

Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 07, 2023

The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.

The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.

Journal: Immunity
Published: March 23, 2023

Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.

Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.

Journal: The Journal of clinical investigation
Published: June 22, 2022

Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiency.

Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiency.

Journal: Communications biology
Published: March 31, 2022

HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.

HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.

Journal: Cancer immunology research
Published: February 24, 2022

Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.

Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.

Journal: Oncogene
Published: November 07, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026